Resource Type

Journal Article 229

Year

2024 2

2023 20

2022 17

2021 24

2020 14

2019 28

2018 14

2017 15

2016 13

2015 7

2014 7

2013 13

2012 4

2011 8

2010 4

2009 15

2008 5

2007 11

2004 2

1999 1

open ︾

Keywords

cancer immunotherapy 3

immunotherapy 3

invasion 3

mesenchymal stem cells 3

CAR T cells 2

COVID-19 2

Cancer 2

Chimeric antigen receptor 2

DNA 2

Efficacy 2

Stem cells 2

carbon-based fuels 2

chimeric antigen receptor T cell 2

embryonic stem cells 2

fuel cells 2

hepatocellular carcinoma 2

ischemic stroke 2

mesenchymal stem cell 2

neuroprotection 2

open ︾

Search scope:

排序： Display mode:

Advances in immunopathogenesis of adult immune thrombocytopenia

Xinguang Liu, Yu Hou, Jun Peng

Frontiers of Medicine 2013, Volume 7, Issue 4,   Pages 418-424 doi: 10.1007/s11684-013-0297-8

Abstract:

Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by immune-mediated accelerated platelet destruction and/or suppressed platelet production. Although the development of autoantibodies against platelet glycoproteins remains central in the pathophysiology of ITP, several abnormalities involving the cellular mechanisms of immune modulation have been identified, and the pathways behind the immune-mediated destruction of platelets have opened new avenues for the design of specific immunotherapies in an attempt to reduce the platelet destruction. This review is primarily focused on the recent literature with respect to immunopathological mechanisms in patients with ITP.

Keywords： primary immune thrombocytopenia     B lymphocytes     T lymphocytes     antigen-presenting cells     cytokines    

HTML PDF Collect

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 322-338 doi: 10.1007/s11684-021-0901-2

Abstract: To date, six chimeric antigen receptor T cell (CAR-T) therapies have been permitted for the treatmentThe simultaneous expression of target antigens by healthy organs and tumor cells is partly responsible

Keywords： cancer immunotherapy     chimeric antigen receptor     solid tumors     tumor-associated antigen     glycosylation    

HTML PDF Collect

Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function ofCD19-specific CAR T-cells via TGF-β signaling

Frontiers of Medicine doi: 10.1007/s11684-023-1010-1

Abstract: Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function ofCD19-specific CAR T-cells via TGF-β signaling

Keywords： exosomes induce activation     impair function CD19     exosomal CD19 antigen    

HTML PDF Collect

CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells

Jiangnan Liu,Bin Yi,Zhe Zhang,Yi Cao

Frontiers of Medicine 2016, Volume 10, Issue 2,   Pages 204-211 doi: 10.1007/s11684-016-0443-1

Abstract:

CD176 (Thomsen-Friedenreich antigen) is a tumor-associated carbohydrate epitope (glycotope) functionallyinvolved in blood spread and liver metastasis of cancer cells by mediating the adhesion of cancer cellsto endothelial cells and hepatocytes, respectively.We applied B lymphocytes obtained from mice immunized with CD176 antigen and constructed a phage displaycells and hepatocytes.

Keywords： CD176     Thomsen-Friedenreich antigen     scFv     cancer     therapy     adhesion     metastasis    

HTML PDF Collect

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 57-68 doi: 10.1007/s11684-019-0683-y

Abstract: In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-TThus, EGFRvIII is a potential antigen for targeted lung cancer therapy.In this study, CAR vectors were constructed and transfected into virus-packaging cells.After infection with retrovirus, CAR was expressed on more than 90% of the T cells.The proliferation of CAR-T cells were induced by cytokine and specific antigen in vitro.

Keywords： chimeric antigen receptor T cells     epidermal growth factor receptor     lung cancer     immunotherapy     tumor immunolog    

HTML PDF Collect

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-Hodgkin

Keywords： anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

HTML PDF Collect

Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Review

Sabrina Wright, Conor Hennessy, Joanna Hester, Fadi Issa

Engineering 2022, Volume 10, Issue 3,   Pages 30-43 doi: 10.1016/j.eng.2021.10.018

Abstract:

Chimeric antigen receptors (CARs) are a breakthrough in genetic engineering that have revolutionizedCells expressing these receptors are rerouted to a predefined target by the inclusion of an antigen-specificThe advantage of cells with programmed specificity has been demonstrated clinically in the field of oncology, and it is clear that such cells have greater accuracy, potency, and reduced off-target therapeuticIn contrast to conventional T cells (Tconvs), regulatory T cells (Tregs) play a major role in suppressing

Keywords： Chimeric antigen receptors     T cell     Treg     Alloimmunity     Bioengineering     Transplant     Autoimmunity    

HTML PDF Collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cellAlthough the identification of an ideal target antigen for AML is challenging, CAR T therapy remains

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation

Xiaodong Mo, Xiaojun Huang

Frontiers of Medicine 2013, Volume 7, Issue 3,   Pages 306-315 doi: 10.1007/s11684-013-0279-x

Abstract: transplantation (HSCT) is one of the most effective options for hematological malignancies, and human leukocyte antigen-partially+positive selection and CD3/CD19 depletion has successfully overcome the human leukocyte antigen

Keywords： partially matched related donor     hematopoietic stem cell transplantation     allogeneic    

HTML PDF Collect

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: Chimeric antigen receptor T (CAR-T) cells were introduced as a treatment for these patients.novel target antigens, such as CD20, CD22, CD30, and CD37, which were greatly expressed on lymphoma cells

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis

Shang-Long LIU, Zi-Fang SONG, Qing-Gang HU, Shao-Bo HU, Jun LI, Qi-Chang ZHENG, Duo SHAN,

Frontiers of Medicine 2010, Volume 4, Issue 4,   Pages 457-462 doi: 10.1007/s11684-010-0240-1

Abstract: This study was performed to determine the prognostic role of preoperative serum carbohydrate antigen

Keywords： cholangiocarcinoma     prognostic factors     serum carbohydrate antigen 19-9    

HTML PDF Collect

Detection and monitoring prostate specific antigen using nanotechnology approaches to biosensing

Grant Perry, Fernando Cortezon-Tamarit, Sofia I. Pascu

Frontiers of Chemical Science and Engineering 2020, Volume 14, Issue 1,   Pages 4-18 doi: 10.1007/s11705-019-1846-8

Abstract: The detection of the prostate specific antigen (PSA) in blood samples has been the preferred method for

Keywords： biosensing     immunosensor     PSA     prostate cancer     fluorescence    

HTML PDF Collect

may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 786-791 doi: 10.1007/s11684-020-0751-3

Abstract: Factors associated with complete and durable remissions after anti-CD19 chimeric antigen receptor T (survival (OS), and progression-free survival (PFS) in patients with r/r NHL treated with anti-CD19 CAR-T cells

Keywords： anti-CD19 chimeric antigen receptor T cell     soft tissue     bone marrow     relapsed or refractory non-Hodgkin    

HTML PDF Collect

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues Review

Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang

Engineering 2019, Volume 5, Issue 1,   Pages 122-131 doi: 10.1016/j.eng.2018.12.003

Abstract:

Adoptive cell therapy using chimeric antigen receptor T (CAR-T) cells, which is a promising cancerCAR-T cells are genetically modified T cells that can specifically recognize tumor specific antigenson the surface of tumor cells, and then effectively kill tumor cells.At present, exciting results are being achieved in clinical applications of CAR-T cells for patientsThe research and development of CAR-T cells for various targets and for the treatment of solid tumors

Keywords： Chimeric antigen receptor T cells     Quality control     Nonclinical research     Safety     Efficacy     Clinical    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellsingle-center phase I dose-escalation study was conducted to evaluate the safety and efficacy of T cells

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting toxicity    

HTML PDF Collect

Title Author Date Type Operation

Advances in immunopathogenesis of adult immune thrombocytopenia

Xinguang Liu, Yu Hou, Jun Peng

Journal Article

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Journal Article

Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function ofCD19-specific CAR T-cells via TGF-β signaling

Journal Article

CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells

Jiangnan Liu,Bin Yi,Zhe Zhang,Yi Cao

Journal Article

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Journal Article

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in

Sabrina Wright, Conor Hennessy, Joanna Hester, Fadi Issa

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation

Xiaodong Mo, Xiaojun Huang

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis

Shang-Long LIU, Zi-Fang SONG, Qing-Gang HU, Shao-Bo HU, Jun LI, Qi-Chang ZHENG, Duo SHAN,

Journal Article

Detection and monitoring prostate specific antigen using nanotechnology approaches to biosensing

Grant Perry, Fernando Cortezon-Tamarit, Sofia I. Pascu

Journal Article

may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Journal Article

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues

Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large

Journal Article